6.26

3.54% -0.23

After Hours: 6.27 0.010 +0.16%

Foghorn Therapeutics Inc (FHTX)

Overview News Price History Option Chain Financials Why FHTX Down? Discussions Forecast

Foghorn Therapeutics Inc stock is traded at $6.26, with a volume of 139.96K. It is down -3.54% in the last 24 hours and up +16.36% over the past month. Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.

Previous Close:

$6.49

Open:

$6.47

24h Volume:

139.96K

Relative Volume:

0.54

Market Cap:

$371.75M

Revenue:

$30.91M

Net Income/Loss:

$-74.28M

P/E Ratio:

-5.1383

EPS:

-1.2183

Net Cash Flow:

$-86.15M

1W Performance:

+3.13%

1M Performance:

+16.36%

6M Performance:

+12.79%

1Y Performance:

+21.67%

1-Day Range:

$6.15

$6.6027

1-Week Range:

$5.95

$6.85

52-Week Range:

$3.27

$6.95

Foghorn Therapeutics Inc Stock (FHTX) Company Profile

Name

Foghorn Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

617-586-3100

Address

500 TECHNOLOGY SQUARE, CAMBRIDGE

Employee

106

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

FHTX's Discussions on Twitter

Compare FHTX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FHTX Foghorn Therapeutics Inc	6.26	394.32M	30.91M	-74.28M	-86.15M	-1.2183
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-17-26	Resumed	Jefferies	Buy
Dec-18-25	Initiated	BTIG Research	Buy
Nov-07-25	Initiated	Guggenheim	Buy
Sep-17-25	Resumed	B. Riley Securities	Buy
Apr-23-25	Initiated	Citizens JMP	Mkt Outperform
Jan-30-25	Initiated	B. Riley Securities	Buy
Sep-03-24	Initiated	Jefferies	Buy
Aug-19-24	Initiated	Evercore ISI	Outperform
Mar-28-23	Initiated	BofA Securities	Buy
Jan-05-23	Initiated	BMO Capital Markets	Outperform
Nov-22-21	Initiated	H.C. Wainwright	Buy
Nov-17-20	Initiated	Cowen	Outperform
Nov-17-20	Initiated	Goldman	Buy
Nov-17-20	Initiated	Morgan Stanley	Overweight
Nov-17-20	Initiated	Wedbush	Outperform

View All

Foghorn Therapeutics Inc Stock (FHTX) Latest News

Aug 14, 2026

Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy - Yahoo Finance

Aug 14, 2026

Aug 13, 2026

Foghorn Therapeutics Inc (NASDAQ: FHTX) Stock Price, News & Analysis - Kalkine

Aug 13, 2026

Aug 12, 2026

News Flash: Analysts Just Made A Huge Upgrade To Their Foghorn Therapeutics Inc. (NASDAQ:FHTX) Forecasts - simplywall.st

Aug 12, 2026

Aug 11, 2026

Enterprise value to EBIT forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView

Aug 11, 2026

HC Wainwright Issues Negative Outlook for FHTX Earnings - marketbeat.com

Aug 11, 2026

Aug 10, 2026

Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade - Yahoo Finance

Aug 10, 2026

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st

Aug 10, 2026

Aug 08, 2026

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - marketbeat.com

Aug 08, 2026

Wall Street Zen Upgrades Foghorn Therapeutics (NASDAQ:FHTX) to Hold - marketbeat.com

Aug 08, 2026

Aug 07, 2026

Foghorn Therapeutics Reports Q2 Results and Pipeline Progress - The Globe and Mail

Aug 07, 2026

H.C. Wainwright Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $13 - Moomoo

Aug 07, 2026

Aug 06, 2026

Discipline and Rules-Based Execution in FHTX Response - Stock Traders Daily

Aug 06, 2026

Foghorn Therapeutics (NASDAQ:FHTX) Issues Earnings Results, Beats Estimates By $0.13 EPS - MarketBeat

Aug 06, 2026

Foghorn Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 06, 2026